Human Genome Sciences HIV Drug Positive In Phase 1
Human Genome Sciences (HGSI) announced following end of trading on Friday that its human monoclonal antibody, HGS004, was tolerated in HIV patients and showed anti-viral activity.
HGS004 specifically targets the chemokine recepter CCR5 that research has shown to have a large role in HIV infections.
The company's other CCR5 drug candidate is HGS101 which is 5.5 times more potent than HGS004 so far in in vitro trials.
Human Genome Sciences will take time to consider its future plans in regards to the best candidate to advance through clinical trials. It might also consider advancing both candidates.
Shares of Human Genome Sciences dropped 1.62% to end trading at $11.54 a share.
It would be interesting to observe how the stock will open on Monday following this positive news.
_
Human Genome Sciences (HGSI) announced following end of trading on Friday that its human monoclonal antibody, HGS004, was tolerated in HIV patients and showed anti-viral activity.
HGS004 specifically targets the chemokine recepter CCR5 that research has shown to have a large role in HIV infections.
The company's other CCR5 drug candidate is HGS101 which is 5.5 times more potent than HGS004 so far in in vitro trials.
Human Genome Sciences will take time to consider its future plans in regards to the best candidate to advance through clinical trials. It might also consider advancing both candidates.
Shares of Human Genome Sciences dropped 1.62% to end trading at $11.54 a share.
It would be interesting to observe how the stock will open on Monday following this positive news.
_
posted by Nico at
12:04 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home